Chronic kidney disease and stromal cell-derived factor 1α peptide-functionalization impact on polycarbonate-bisurea based in situ tissue-engineered vascular graft dynamics Authors: M. M. Krebber, P. J. Besseling, R. C. H. Driessen, A. M. Lichauco, W. Szymczyk, S. H. M. Söntjens, H. M. Janssen, M. Teraa, J. O. Fledderus, A. I. P. M. Smits, P. Y. W. Dankers, C. V. C. Bouten, M. C. Verhaar Published: 2026 ABSTRACT Bioresorbable grafts offer promise for in situ tissue engineered blood vessels (TEBVs), yet balancing graft degradation and neo-tissue formation remains challenging. Chronic kidney disease (CKD) may affect this balance, potentially limiting TEBV effectiveness in CKD-patients. To investigate this, we implanted electrospun, polycarbonate-bisurea (PC-BU) TEBVs in healthy (sham) and 5/6th-nephrectomy-induced CKD rats. Additionally, we evaluated whether stromal cell-derived factor 1α (SDF-1α)-peptide functionalization improved outcomes. TEBVs were explanted after two weeks (sham or CKD) or three months (sham). After two weeks, patency was 100% in sham (n = 13) and CKD (n = 12) explants, all containing an endothelial lining (RECA), smooth muscle (αSMA) and inflammatory (CD68) cells. Graft degradation was evident in all groups with similar uniaxial tensile strength independent of group or timepoint. Lumen dilatation was observed in three-month sham explants (n = 8), accompanied by limited inflammation. From three weeks post-implantation onwards, graft degradation-related TEBV rupture and fatality occurred in n = 4 sham. The CKD arm was discontinued due to rapid disease progression. Independent of disease or timepoint, SDF-1α-peptide-functionalization did not impact patency, tissue formation or graft degradation. In conclusion, PC-BU TEBVs supported rapid neo-tissue formation and maturation but were prone to unpredicted failure. Neither CKD nor SDF-1α functionalization influenced patency, neo-tissue formation or graft degradation.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-57465-7. Introduction Cardiovascular disease (CVD) remains the leading cause of death worldwide, creating an urgent clinical need for viable small-diameter vascular grafts1,2, including grafts for patients with chronic kidney disease (CKD) who often need vascular access to initiate dialysis3. Autologous veins are generally a preferred small-diameter graft source because of their long-term patency and low risk of infection4. However, they are often unavailable due to preexisting vascular pathology or show insufficient maturation post-surgery. Alternatively, non-degradable synthetic grafts have off-the-shelf functionality but are associated with poor long-term patency and high complication rates, including thrombosis and infection, due to their lack of adaptive and self-healing capacity2,4. In situ tissue engineering (TE) combines the immediate functionality of synthetic grafts with the long-term advantages of autologous vessels. This in situ TE approach uses biodegradable grafts that gradually transform into autologous vascular tissue at the site of implantation through inflammation-driven regeneration1,5. Circulating and resident immune-, stem- and tissue cells infiltrate the vascular graft, slowly forming mature vascular neo-tissue in a sequence that is analogue to wound healing. In parallel, immune activation promotes graft material degradation6. The clinical success of in situ TE blood vessels (TEBVs) critically depends on maintaining an adequate balance between graft degradation and neo-tissue formation, safeguarding integrity but preventing structural failure or chronic inflammation1,5,7. Conditions impacting neo-tissue formation and/or graft stability may, therefore, disrupt the process of in situ vascular TE. Notably, CKD is associated with a chronic inflammatory state8,9, endothelial dysfunction10,11 and reduced regenerative capacity12, all of which may compromise the balance between neo-tissue formation and graft degradation and thus vascular in situ TE outcomes. Our prior research established that the presence of CKD in rats did not affect the patency and mechanical stability of in situ small-diameter TEBVs synthesized from the slow-degrading supramolecular elastomer polycarbonate–ureido-pyrimidinone (PC-UPy)13. However, the extended presence of these slow degrading grafts might hinder the formation of neo-tissue and cause chronic inflammation, fibrosis, calcifications of new vessels and potentially negative outcomes over time5,6. Supramolecular materials designed to degrade faster may accelerate neo-tissue formation, including endothelization, and minimize adverse effects but whether and how CKD affects functional neo-vascular tissue formation in this setting is unclear. Building on our previous findings that functionalization of biomaterials with peptides derived from the stromal cell-derived factor 1α receptor-activating domain (SDF-1α), an important chemoattractant for immune- and progenitor cells involved in tissue formation, enhances cell recruitment into the grafts14–17, we further investigated the influence of SDF-1α functionalization on neo-vascular tissue formation under CKD conditions. The aim of our study was to gain understanding of the effect of CKD on neo-vascular tissue formation in vascular in situ tissue engineering, using faster-degrading, supramolecular materials, with or without chemoattracting SDF-1α biofunctionalization. To address this, we employed supramolecular, electrospun polycarbonate-bisurea (PC-BU) grafts for vascular in situ TEBV purposes. Compared with the previously used PC-UPy, PC-BU scaffolds degrade faster18, which we hypothesize promotes more pronounced neo-tissue formation. In parallel, they retained their vascular mechanical integrity during the in vivo analysis period of 1 year18, supported by in vitro19 data, and after implantation as TE pulmonary20 and aortic heart valves21 in sheep. We evaluated the performance of these PC-BU TEBVs in a rat aortic interposition model, with a focus on patency, graft degradation, neo-tissue formation, and mechanical stability. To evaluate the specific impact of CKD on these in situ vascular TE processes, we used a 5/6th nephrectomy rat model (adapted from22), which closely simulates the systemic conditions observed in human CKD patients22,23. Materials and methods Animal model Female Sprague Dawley rats (SD, n = 53, Jackson laboratories, Envigo) aged 7 weeks and weighing > 200 g were group housed up to 4 animals and kept under standardized conditions in a light-, humidity- and temperature-controlled environment. Animals had ad libitum access to food and water and were acclimated to the laboratory conditions for 7 days prior to start. The study protocol was approved by the Animal Ethics Committee of the University of Utrecht (CCD—AVD1150020173344), in agreement with the current Dutch law on animal experiments and in accordance with ARRIVE guidelines. Female animals were chosen specifically due to their slower growth curve compared to males, eliminating possible diameter mismatches in native vasculature versus graft. Moreover, male hormones tend to accelerate CKD severity24. After baseline longitudinal measurements at week 8 (experimental week 0), animals were stratified and allocated based on proteinuria (primary outcome), weight and uremia (secondary outcomes) into groups as follows: sham PC-BU pristine, control rats undergoing sham surgery, in which a pristine (e.g. without bio-functionalization) aortic vascular graft with PC-BU was implanted; CKD PC-BU pristine, rats undergoing CKD surgery, in which a pristine (e.g. without bio-functionalization) aortic vascular graft with PC-BU was implanted; sham PC-BU + SDF-1α, control rats undergoing sham surgery, in which an aortic vascular graft with PC-BU-SDF-1α biofunctionalization was implanted; CKD PC-BU + SDF-1α, rats undergoing CKD surgery, in which an aortic vascular graft with PC-BU + SDF-1α biofunctionalization was implanted. CKD or sham surgery was performed in week 9. CKD was induced under isoflurane anesthesia (4% induction, 2% maintenance and 0,8 L O2) by a single-step 5/6th nephrectomy (SNX) procedure with uninephrectomy of the left kidney and polectomy (total amount of kidney removed: 59 ± 6%, n = 24) of the right kidney using retroperitoneal incisions. In sham, kidneys were externalized, and the renal capsule was removed. The muscles were closed using continuous sutures (5.0 Vicryl, Ethicon V303H) and the skin using continuous intracutaneous sutures (4.0 Vicryl, Ethicon V392H). Animals received Buprenorphine (Temgesic, s.c. 0.01 mg/kg) pre-surgery, Lidocaine (topically 4 mg/kg) and Bupivacaine (topically 1 mg/kg) during surgery and Buprenorphine (Temgesic, s.c. 0.05 mg/kg in a 12 h-interval) for 48 h post-surgery. Post-surgery, animals were individually housed on a heat pad overnight before being housed back in groups. Power calculation An a priori power calculation was performed using G*Power 3.1.9. The calculation was based on an F-test: fixed-effects, omnibus, one-way ANOVA with a given a = 0.05, power = 0.95, and effect size f = 0.89 (n = 8 experimental groups with equal SDs). The total calculated sample size was n = 40 e.g., n = 5 animals per experimental groups. With a correction for predicted survival of both CKD and implant failure (lack of patency), n = 6 per CKD and n = 7 per sham was chosen. Longitudinal measurements Weighing of the animals was performed weekly pre- and post-implantation. Every other week prior to implantation, 24-h urine and blood samples were collected, together with systolic blood pressure (SBP). Post-implantation, animals in the two-week protocol underwent measurements once before termination, the animals in the three-month protocol were measured monthly. 24-h urine was collected on an antibiotic–antimycotic solution (A5955; Sigma, St Louis, US). During this period, rats had free access to tap water with 2% glucose but no solid food. Blood was collected via the tail vein under isoflurane anesthesia on EDTA (Microtainers, BD #365,974). SBP was measured by tail cuff sphygmomanometry (LE 5002 Storage Pressure Meter). Urinary protein levels were measured by Bradford Assay (BioRad). Plasma urea was determined by DiaSys Urea CT FS (DiaSys Diagnostic Systems, Holzheim, Germany). Plasma creatinine levels were determined by DiaSys Creatinine PAP FS kit (DiaSys Diagnostic Systems, Holzheim, Germany). Estimated glomerular filtration rate (eGFR) was calculated with a plasma creatinine- and urea-based equation specific for rats25. Supramolecular polymer synthesis and vascular graft fabrication and implantation PC-BU synthesis Polycarbonate-bisurea was synthesized as described previously19–21. PC-BU consists of uniform and strictly segmented poly-(hexylcarbonate) soft blocks and butylene bisurea hard blocks, see Fig. 1.Fig. 1Graft synthesis, functionalization and mechanical characteristics. (A) Chemical structure of biodegradable supramolecular polycarbonate-bisurea (PC-BU) and the PC-BU-SDF-1α linker. (B) Representative gross view of electrospun grafts with ID: 1400 μm (left) and scanning electron microscopy (SEM) cross-section of supramolecular pristine (middle) or PC-BU + SDF-1α grafts (right). Wall thickness pristine: 279 ± 37 um, magnification 100x and SDF-1α: 299 ± 21 μm, magnification 90x. *p < 0.01, unpaired T-test. Scalebars represent 1 mm. (C) Scanning electron microscopy (SEM) of explants at two weeks, (D) three months, (E) pre-implantation and representative rupture. Magnification 500x and 5000x, with 500x scalebar representing 100 μm and 5000 × 10 μm. (F) Uniaxial tensile test of Modulus (mPA) at 70% strain for explants after two weeks and three months. (G) Lumen diameter of explants after two weeks and three months compared to ID at implantation (dotted line). Red circles in A-C denote locations with fiber erosion and/or fiber breaks. One-way ANOVA with Tukey’s post-hoc. ***p < 0.001. Graft synthesis, functionalization and mechanical characteristics. (A) Chemical structure of biodegradable supramolecular polycarbonate-bisurea (PC-BU) and the PC-BU-SDF-1α linker. (B) Representative gross view of electrospun grafts with ID: 1400 μm (left) and scanning electron microscopy (SEM) cross-section of supramolecular pristine (middle) or PC-BU + SDF-1α grafts (right). Wall thickness pristine: 279 ± 37 um, magnification 100x and SDF-1α: 299 ± 21 μm, magnification 90x. *p < 0.01, unpaired T-test. Scalebars represent 1 mm. (C) Scanning electron microscopy (SEM) of explants at two weeks, (D) three months, (E) pre-implantation and representative rupture. Magnification 500x and 5000x, with 500x scalebar representing 100 μm and 5000 × 10 μm. (F) Uniaxial tensile test of Modulus (mPA) at 70% strain for explants after two weeks and three months. (G) Lumen diameter of explants after two weeks and three months compared to ID at implantation (dotted line). Red circles in A-C denote locations with fiber erosion and/or fiber breaks. One-way ANOVA with Tukey’s post-hoc. ***p < 0.001. SDF-1a synthesis SDF-1α -BU peptide synthesis was performed as described previously14,26. Graft fabrication Fibrous grafts, with a length of 2 cm, an inner diameter of 1400 µm, and a wall thickness ranging from 250 to 300 µm, were produced via electrospinning using a PC-BU polymer solvent at a concentration of 23% w/v. The solvent mixture comprised 85% chloroform and 15% HFIP, and electrospinning was carried out using an IME Technologies electrospinning device. The initial layer was electrospun with a solution flow rate of 90 µL/min, charged to 17 kV, onto a 1.4 mm diameter stainless steel target situated in a climate-controlled chamber maintained at 23 ºC and 50% humidity. The nozzle underwent translation at a speed of 12 mm/s. Simultaneously, the target rotated at a speed of 50 rpm and was charged from 0 kV to -3 kV over 900 s starting from the activation of the high voltage. The graft thickness was continuously monitored with a laser module during electrospinning, resulting in a final thickness of 275 ± 25 µm. Wall thickness per graft was confirmed by analyzing n = 11 (lumen to outer rim, µm) at two random locations, totaling n = 22 datapoints. Subsequently, the grafts were placed in a vacuum overnight to facilitate the evaporation of any remaining solvent before being removed from the target. Prior to surgical implantation as aortic interposition grafts, grafts were sterilized using ethylene oxide by Synergy Health, Venlo in accordance with the certified standards ISO 11135 and ISO 13485. Graft implantation TEBV implantation was performed as aorta anastomosis in CKD animals (n = 19) after reaching the threshold value for proteinuria (> 50 mg/24 h). Sham animals were age-matched implanted. Aorta anastomosis was performed under isoflurane anesthesia after the abdominal viscera were externalized in damp cloth by dissecting the abdominal aorta from the inferior vena cava between the right renal artery and the bifurcation of the femoral artery. Collateral branches of the aorta were ligated (6.0 Prolene, Ethicon 8719H) and 20 U of heparin was given i.v. through the tail vein before the aorta was clamped (ST ABB-2) proximally and distally and cut in between. Vascular grafts, either PC-BU pristine or PC-BU + SDF-1α, were randomly allocated and the 2 cm interposition grafts were implanted using end-to-end anastomosis with interrupted sutures between the renal artery and the bifurcation to the femoral artery (9.0 ETHILON, Ethicon 2809G) by an experienced surgeon blinded to the experimental settings. Immediately after releasing the clamps, the patency of the graft was visually confirmed in all animals. Ability to show grip-strength of the hind limbs, as a proxy of functional blood flow, was assessed daily up until three days post-surgery using the cage-lid test27. Upon completion of the study, animals were anesthetized with isoflurane and euthanized via exsanguination through cardiac puncture. Grafts and pertinent organs were then dissected from surrounding tissue, segmented in accordance with a pre-set scheme see supplemental Figure S1, and preserved for subsequent analysis. Mechanical testing of explanted grafts For mechanical characterization, 2 mm long explanted graft segments were retrieved and gradually frozen in freezing medium (10% FCS, 10% DMSO in DMEM) in a Mr. Frosty™ and stored at –80 ⁰C until mechanical characterization of all samples. To this end, samples were gradually thawed until room temperature. The dimensions of each segment were recorded with a calibrated digital microscope (VHC-500FE, Keyence, Mechelen, Belgium). The elastic moduli of the explants were determined from a uniaxial ring test on 2 mm wide ring-sections of the grafts28,29 (BioTester, 1.5 or 5 N load cell; CellScale) in combination with LabJoy software (V10.77, CellScale). For the ring tests, custom-made hooks were made by welding fishing hooks (Preston KKH-B size 10) onto M5 nuts. For each test, the zero-strain position was defined as 40% of the inner circumference of the graft segment. Each test consisted of 5 cycles of 10% incremental strain, up to 100% strain. All measurements were performed at a strain rate of 100% a minute. The modulus for each strain regime was calculated from the slope of the last 2.5% of the stress–strain curve of the last cycle. Scanning electron microscopy analysis Graft degradation was analyzed by scanning electron microscopy (SEM). Neo-tissue was removed by 4.6% (v/v) sodium hypochlorite (Clorox) incubation for 15 min at room temperature. Afterwards the tissues were washed twice in PBS and ultrapure water, followed by dehydration in a graded ethanol series. The samples were dried using a critical point dryer (CPD300, Leica, Austria) and visualized by SEM (Quanta 600F, FEI, Eindhoven). Images were acquired at 500 × and 5000 × magnification. Fiber diameter analysis was conducted on SEM images using ImageJ, averaging measurements from 20 fibers per image (ImageJ open software, version 1.53 k, National Institutes of Health, Bethesda, MD, USA). Histology and immunohistochemical staining Whole cross-section vascular explants, Supplemental Figure S1, and kidney remnants were fixed in 4% PFA and embedded into paraffin for sectioning, 5 and 3 μm respectively, before staining. Kidneys and whole cross-section vascular explants were stained with hematoxylin and eosin (H&E) and Periodic Acid Schiff (PAS) for general histology. For PAS, after incubation with 1% periodic acid, slides were stained in Schiffs reagent in the dark and counterstained with hematoxylin. Von Kossa for was performed using standard techniques. Masson’s Trichrome (MT) for fibrosis and extracellular matrix formation was performed by incubation of slides in Bouin Fluid at 56 °C for 1 h, followed by 8 min of Celestine Blue at room temperature. Slides were subsequently stained with Mayers hematoxylin and aqueous Biebrich Scarlet-Acid Fuchsin, both for 5 min. Differentiation took place in Phosphomolybdic–Phosphotungstic Acid solution for 15 min at room temperature, followed by Aniline Blue (10 min) and 1% aqueous acetic acid (1 min). Explants were moreover stained after blocking with 5% hydrogen peroxide in PBS, indirect heat-induced antigen retrieval (TRIS/EDTA, pH 9.0 or Citrate pH 6.0), and blocking with Superblock™ (Thermo Fischer Scientific). Elastin was treated with 0,1% pronase followed by blocking with 2% PBS/BSA. Primary antibodies were incubated for 1 h at room temperature; ED1 (CD68, Mo-α-ED-1, pan-macrophage marker, ab31630, 1:250; Abcam), Elastin (Mo-α-Elastin, elastic lamellae, 1:100, MAB2503, Millipore), and Vimentin (Rb-a-Vimentin, fibroblast marker; ab92547, 1:200; Abcam). Secondary antibodies, Gt-α-Mo poly-HRP (ED1, Elastin—Brightvision, Immunologic) or Gt-α-Rb poly HRP (Vimentin—Brightvision, Immunologic) were incubated for 30 min. Whole cross-sections were scanned and digitized with a NanoZoomer S360 (Hamamatsu C13220). Positive area was analyzed on whole cross-sections using CellProfiler30,31, see Supplementary Methods and Supplementary Fig. 2. Immunofluorescence Whole cross-section vascular explants (Supplemental Figure S1) were fixed in 4% PFA with 15% sucrose, followed by 15% sucrose without fixative, 30% sucrose and embedded in OCT Tissue-Tek (Sakura #4583). 5 μm sections were stained for rat specific endothelial marker (RECA; Mo-α-rat RECA, MCA970R, 1:100, Serotec), enhanced using TSA Plus Fluorescein (FITC 1:50, Perkin Elmer, Life Sciences) followed by αMo-poly-HRP (Brightvision, Immunologic), early smooth muscle marker αSMA (αSMA-Cy3, C6198, 1:500; Sigma) and nuclear DAPI (1:5000, Thermo Fisher Scientific) counterstain. Cross-sections were imaged with a Leica DMi8 THUNDER Imager. RNA isolation, cDNA synthesis and qPCR RNA was isolated from snap-frozen native abdominal aortas and vascular graft explants using Trizol reagent (Invitrogen, CA, USA) and an Ultra Turrax homogenizer. RNA (200 ng) was reverse transcribed using the Bioline SensiFAST™ cDNA Synthesis Kit (Bioline #BIO-65054). A total of 4 ng cDNA was used for quantitative gene expression analysis, see Supplemental Table 1 for primers, with FastStart Universal SYBR Green (Roche #4,913,914,001). B2M and GAPDH were used as standard housekeeping genes. The relative mRNA expression levels were determined using the 2-∆CT method.Table 1Animal characteristics at baseline and pre-TEBV implantation.BaselinePre-implantationsham (n)CKD (n)p-valuesham (n)CKD (n)p-valueWeight (g)243 ± 12 (22)247 ± 9 (13)NS0.14263 ± 20 (22)261 ± 11 (13)NS0.63SBP (mm/Hg)137 ± 14 (22)140 ± 9 (10)NS0.55129 ± 21 (14)151 ± 17 (7)0.03Proteinuria (mg/24 h)4.1 ± 4.6 (22)4.3 ± 4.8 (13)NS0.444.4 ± 4.5 (22)91.9 ± 41 (13) < 0.0001Urea (mmol/l)6.3 ± 0.9 (22)6.4 ± 1.0 (13)NS0.857.0 ± 1.3 (22)22 ± 4.0 (13) < 0.0001Creatinine (µmol/l)60.7 ± 32.9 (17)66.2 ± 34.7 (13)NS0.8067.6 ± 33.7 (17)125.5 ± 28.2 (13) < 0.0001eGFR 25mL/min/100 g BW1338 ± 468 (17)1325 ± 648 (13)NS0.951246 ± 532 (17)351 ± 116 (13) < 0.0001Animals were allocated to either sham or CKD based on baseline measurements of proteinuria. Pre-TEBV implant, CKD animals developed clear kidney failure. Only animals reaching their respective endpoint were included in analyses, with n = 22 for Sham and n = 13 for CKD. Not all measurements were performed for each animal, denoted in brackets per respective measurement. Unpaired T-test or non-parametric Mann–Whitney test. eGFR estimated glomerular filtration rate, SBP systolic blood pressure. Table 1Animal characteristics at baseline and pre-TEBV implantation.BaselinePre-implantationsham (n)CKD (n)p-valuesham (n)CKD (n)p-valueWeight (g)243 ± 12 (22)247 ± 9 (13)NS0.14263 ± 20 (22)261 ± 11 (13)NS0.63SBP (mm/Hg)137 ± 14 (22)140 ± 9 (10)NS0.55129 ± 21 (14)151 ± 17 (7)0.03Proteinuria (mg/24 h)4.1 ± 4.6 (22)4.3 ± 4.8 (13)NS0.444.4 ± 4.5 (22)91.9 ± 41 (13) < 0.0001Urea (mmol/l)6.3 ± 0.9 (22)6.4 ± 1.0 (13)NS0.857.0 ± 1.3 (22)22 ± 4.0 (13) < 0.0001Creatinine (µmol/l)60.7 ± 32.9 (17)66.2 ± 34.7 (13)NS0.8067.6 ± 33.7 (17)125.5 ± 28.2 (13) < 0.0001eGFR 25mL/min/100 g BW1338 ± 468 (17)1325 ± 648 (13)NS0.951246 ± 532 (17)351 ± 116 (13) < 0.0001Animals were allocated to either sham or CKD based on baseline measurements of proteinuria. Pre-TEBV implant, CKD animals developed clear kidney failure. Only animals reaching their respective endpoint were included in analyses, with n = 22 for Sham and n = 13 for CKD. Not all measurements were performed for each animal, denoted in brackets per respective measurement. Unpaired T-test or non-parametric Mann–Whitney test. eGFR estimated glomerular filtration rate, SBP systolic blood pressure. Animal characteristics at baseline and pre-TEBV implantation. NS 0.14 NS 0.63 NS 0.55 NS 0.44 NS 0.85 NS 0.80 eGFR 25 mL/min/100 g BW NS 0.95 Animals were allocated to either sham or CKD based on baseline measurements of proteinuria. Pre-TEBV implant, CKD animals developed clear kidney failure. Only animals reaching their respective endpoint were included in analyses, with n = 22 for Sham and n = 13 for CKD. Not all measurements were performed for each animal, denoted in brackets per respective measurement. Unpaired T-test or non-parametric Mann–Whitney test. eGFR estimated glomerular filtration rate, SBP systolic blood pressure. Statistical analysis Results are shown as mean ± SD and p < 0.05 was indicated as significant. Outliers were identified using ROUT. Data normality was tested using the Shapiro–Wilk normality test and where applicable, data were transformed. Graft wall thickness and lumen diameter were compared using two-tailed t-test. Immunohistochemical data and uniaxial tension tests were analyzed using either one-way ANOVA with Tukey post-hoc or Kruskal–Wallis for non-parametric distributions. Analyses were performed using Graphpad Prism 10. Results Vascular graft and animal characteristics TEBVs were synthesized to investigate the influence of CKD and SDF-1α biofunctionalization on vascular in situ TE outcomes of rapidly-degrading PC-BU grafts. First, PC-BU pristine and PC-BU + SDF-1α vascular graft were electrospun with an inner diameter of 1400 µm and a length of 2 cm, Fig. 1A for chemical structure, Fig. 1B—left for representative grafts. The walls of the PC-BU + SDF-1α were significantly thicker than those of the PC-BU pristine grafts (299 ± 21 mm versus 279 ± 37 µm; p = 0.02, Fig. 1B—middle PC-BU pristine and Fig. 1B—right PC-BU + SDF-1α for representative pictures, Supplemental Figure S3A for individual datapoints and Supplemental Figure S3B for a low magnification (30x) overview of fiber structure. Fiber diameter was significantly smaller (2.9 ± 0.6 µm in PC-BU + SDF-1α versus 3.2 ± 0.7 µm in PC-BU pristine; p = 0.01). Animal characteristics and survival In total, n = 53 female Sprague–Dawley rats were included in the study and animals underwent either sham surgery (sham, n = 29) or 5/6th nephrectomy (CKD, n = 24). The average time from CKD induction reaching the proteinuria threshold of 50 mg/24 h for graft implantation was 8 ± 3 weeks. Pre-implantation. n = 3 CKD and n = 1 sham reached humane endpoints (HEP), a pre-set list including acute weight loss (< 15% in 7 days) and decline in general health, see Supplemental Figure S4 for survival and patency throughout the study. Pre-implantation, CKD animals as well demonstrated increased plasma urea and creatinine and lower estimated glomerular filtration rate 25, all human CKD characteristics 23, see Table 1. In total, PC-BU TEBVs were implanted in n = 49 animals (n = 28 sham and n = 19 CKD). Mean ischemia time (46 ± 11 min) was independent of disease status or graft functionalization. Survival and vascular patency were 100% 24 h post-surgery and at the two-week endpoint, in line with visual confirmation of flow and adequate hind-limb grip strength (n = 13 sham and n = 12 CKD for two-week endpoint). Irrespective of disease or graft functionalization, ‘soft spots’ were noted in the grafts (Supplemental Figure S5). Explants at three months included n = 8 sham, all of which were patent but showed major dilatations, aneurysm formation, and thrombosis but no stenosis (Supplemental Figure S5). CKD animals did not reach the three-month protocol endpoint (n = 7). The progressive nature of the single-surgery CKD-induction resulted in severe kidney failure and premature HEPs, warranting the decision not to continue with the three-month CKD protocol. In parallel, acute graft rupture and abdominal bleeding occurred in n = 4 sham animals, leading to sudden death (n = 2 sham PC-BU pristine and n = 2 sham PC-BU + SDF-1α, with the first occurrence three weeks post-implantation, Supplemental Figure S5 for representative example of ruptured explant). Two additional sham animals reached study unrelated HEPs. For explant analyses, only animals that completed their respective protocol were included, in total n = 33. Mechanical characterization of explants Scanning electron microscopy (SEM) images of Chlorox-treated explants, removing infiltrated cells, are shown in Fig. 1C-E. Two-week explants, irrespective of disease or functionalization, showed a dispersed pattern of intact graft fibers, fiber erosion, and fiber breaks. At this timepoint, explanted sham pristine PC-BU fibers were larger in diameter than sham PC-BU + SDF-1α (sham pristine PC-BU 3.36 ± 0.27 µm versus sham PC-BU + SDF-1α 2.73 ± 0.26 µm) whereas CKD pristine PC-BU (3.13 ± 0.20 µm) and CKD PC-BU + SDF-1α (3.06 ± 0.26 µm) showed similar fiber thickness. After three months, fiber degradation had progressed irrespective of the material, but the remaining fibers showed a similar diameter. Uniaxial tensile tests, Fig. 1F, revealed no differences in elastic moduli at 70% strain induction between PC-BU or PC-BU + SDF-1α explants at three months. Elastic moduli for all explants between 10—100% strain can be found in Supplemental Figure S6. Lumen diameter, Fig. 1G, at three months was similar between groups but significantly higher compared to two-week explants (two weeks: 1726 ± 113 µm versus three months 5055 ± 718 µm, p < 0.0001), suggesting dilation. Vascular tissue morphology To verify neo-tissue formation, TEBV explant morphology was investigated. Traces of collagen were present on the outer adventitial rim of two-week explants, Fig. 2A, using Masson Trichrome staining and patterns of deposition appeared similar between experimental. No visual differences were found in total cellularity per location. Three-month sham explants showed enhanced collagen expression, penetrating the medial layers, Fig. 2B. In line with overall wall thinning, we found no signs of neo-intima formation. Subsequently, the explants were stained for endothelial cells (endothelial cell antigen, RECA) and smooth muscle cells (SMCs). Two-week explants already showed endothelial lining formation, Fig. 3A. Endothelial cells were also present on the adventitial side, appearing to grow inwards to form vasa vasorum (arrows, Fig. 3A). αSMA presence as a marker of early smooth muscle cells was primarily found on the abluminal side and showed a dispersed pattern. There were no visual differences in positive area and patterns of RECA or αSMA between the groups. Three-month PC-BU + SDF-1α explants appeared to show increased αSMA alignment and a clear endothelial monolayer. RECA or αSMA could not be visualized for three-month PC-BU explants. Explants were also positive for mature smooth muscle cell marker Calponin, increasing non-significantly over time, Fig. 3B-3D. Both at two weeks and three months, explants stained positive for Elastin, Fig. 4. Both Calponin and Elastin expression was significantly lower compared to the native aorta (histology not shown for Calponin). We found no differences in vimentin staining as a marker of fibroblasts, Fig. 5. Two-week explants showed almost no calcifications (Von Kossa), with no differences between groups, Fig. 6. Three-month explants of sham pristine PC-BU and sham pristine PC-BU + SDF-1α both showed a more pronounced but non-significant increase in calcifications versus all two-week explants. These primarily occurred at the interface between the (intimal) neo-tissue and the remaining graft material or around spots of excessive graft degradation. Regarding inflammatory status, two-week explants showed pronounced inflammation, marked by the presence of macrophage CD68 (ED-1) cells, Fig. 7. CKD PC-BU pristine explants showed a tendency towards more CD68 inflammation compared to sham PC-BU pristine. Inflammation appeared to subside partly at three months.Fig. 2Extracellular matrix. (A) Representative photographs of mid- or endpiece cross-section explants per experimental group with staining of Masson Trichrome, magnification 2,5x (two weeks) and 1,25 × or 0,5x (three months). (B) Detailed magnification 10x (two weeks) and 5x (three months). Lumen is indicated by asterisks. Scalebars represent 100 mm. Colors indicate cytoplasm (pink), collagen (blue), and nuclei (dark blue). Electrospun fibers are visible in white.Fig. 3Endothelium and (mature) smooth muscle cells. (A) Immunofluorescent staining of endothelial (rat endothelial cell antigen—RECA, green), smooth muscle cells (αSMA, red) and cell nuclei (DAPI, blue). Representative photos of endpiece explants per experimental group at two weeks, native aorta and sham + PC-BU + SDF-1α (3 months). Lumen is indicated by asterisks, arrowheads indicate vaso vasorum formation. Magnification 100x. Scalebars represent 1 mm. (B) Representative photographs of mid- or endpiece explants per experimental group at two weeks and (C) three months, with immunohistochemical staining of Calponin (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10x (two weeks and native aorta) and 5x (three months). Scalebars represent 1 mm. (D) Analysis of Calponin positive surface area. One-way ANOVA with Tukey’s post-hoc. *p < 0.05.Fig. 4Presence of Elastin. (A) Representative photographs of mid- or endpiece explants per experimental group or (B) native aorta with immunohistochemical staining of Elastin (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10 × or 2,5x. Scalebars represent 100 mm. (C) Analysis of Elastin+ surface area. One-way ANOVA with Tukey’s post-hoc. ****p < 0.0001.Fig. 5Presence of fibroblasts. (A) Representative photographs of mid- or endpiece explants per experimental group with immunohistochemical staining of Vimentin (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10x (two weeks) and 2,5 x or 5X (three months). Scalebars represent 100 mm. (B) Analysis of Vimentin+ surface area. Kruskal–Wallis with Dunn’s post-hoc; n.s.Fig. 6Presence of calcifications. (A) Representative photographs of mid- or endpiece cross-section explants per experimental group with staining of Von Kossa (black). Magnification 2,5x (two weeks) and 0,8x (three months). Scalebars represent 250 mm. (B) Analysis of Von Kossa+ surface area. Kruskal–Wallis with Dunn’s post-hoc; n.s.Fig. 7Presence of inflammatory cells. (A) Representative photographs of mid- or endpiece explants per experimental group with immunohistochemical staining of CD68 (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10x. Scalebars represent 100 mm. (B) Analysis of CD68+ surface area. Kruskal–Wallis with Dunn’s post-hoc. *p < 0.05. Extracellular matrix. (A) Representative photographs of mid- or endpiece cross-section explants per experimental group with staining of Masson Trichrome, magnification 2,5x (two weeks) and 1,25 × or 0,5x (three months). (B) Detailed magnification 10x (two weeks) and 5x (three months). Lumen is indicated by asterisks. Scalebars represent 100 mm. Colors indicate cytoplasm (pink), collagen (blue), and nuclei (dark blue). Electrospun fibers are visible in white. Endothelium and (mature) smooth muscle cells. (A) Immunofluorescent staining of endothelial (rat endothelial cell antigen—RECA, green), smooth muscle cells (αSMA, red) and cell nuclei (DAPI, blue). Representative photos of endpiece explants per experimental group at two weeks, native aorta and sham + PC-BU + SDF-1α (3 months). Lumen is indicated by asterisks, arrowheads indicate vaso vasorum formation. Magnification 100x. Scalebars represent 1 mm. (B) Representative photographs of mid- or endpiece explants per experimental group at two weeks and (C) three months, with immunohistochemical staining of Calponin (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10x (two weeks and native aorta) and 5x (three months). Scalebars represent 1 mm. (D) Analysis of Calponin positive surface area. One-way ANOVA with Tukey’s post-hoc. *p < 0.05. Presence of Elastin. (A) Representative photographs of mid- or endpiece explants per experimental group or (B) native aorta with immunohistochemical staining of Elastin (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10 × or 2,5x. Scalebars represent 100 mm. (C) Analysis of Elastin+ surface area. One-way ANOVA with Tukey’s post-hoc. ****p < 0.0001. Presence of fibroblasts. (A) Representative photographs of mid- or endpiece explants per experimental group with immunohistochemical staining of Vimentin (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10x (two weeks) and 2,5 x or 5X (three months). Scalebars represent 100 mm. (B) Analysis of Vimentin+ surface area. Kruskal–Wallis with Dunn’s post-hoc; n.s. Presence of calcifications. (A) Representative photographs of mid- or endpiece cross-section explants per experimental group with staining of Von Kossa (black). Magnification 2,5x (two weeks) and 0,8x (three months). Scalebars represent 250 mm. (B) Analysis of Von Kossa+ surface area. Kruskal–Wallis with Dunn’s post-hoc; n.s. Presence of inflammatory cells. (A) Representative photographs of mid- or endpiece explants per experimental group with immunohistochemical staining of CD68 (brown), counterstained by hematoxylin (purple). Lumen is indicated by asterisks. Magnification 10x. Scalebars represent 100 mm. (B) Analysis of CD68+ surface area. Kruskal–Wallis with Dunn’s post-hoc. *p < 0.05. Gene expression We subsequently investigated gene expression markers in TEBV mid-piece explants. Thrombospondin 1 (TSP-1) expression, important in extracellular matrix deposition and remodeling, was significantly different between explants (p = 0.035) but multiple comparison analyses could not attribute this to specific groups, (Fig. 8). Moreover, gene expression of pro-inflammatory IL-6 (p = 0.059) and MCP-1 (p = 0.054) and Elastin (p = 0.053) approached significance. Extracellular matrix markers Collagen I (p = 0.32) and Collagen III (p = 0.73) and anti-inflammatory IL-10 (p = 0.58) and TGF-b (p = 0.36) were similar between groups. Aortic gene expression levels are shown as reference.Fig. 8Heatmap of explant gene expression patterns. Gene expression as determined by qPCR and analyzed as 2^-∆CT for pro-inflammatory, anti-inflammatory and ECM-related genes of mid-piece explants. Aortic gene expression is shown as reference but was not included in the statistical testing. One-way ANOVA with Tukey’s post-hoc or Kruskal–Wallis with Dunn’s posthoc. See Supplemental Table 1 for group sizes per gene targets. *p < 0.05 for Thrombospondin. Heatmap of explant gene expression patterns. Gene expression as determined by qPCR and analyzed as 2^-∆CT for pro-inflammatory, anti-inflammatory and ECM-related genes of mid-piece explants. Aortic gene expression is shown as reference but was not included in the statistical testing. One-way ANOVA with Tukey’s post-hoc or Kruskal–Wallis with Dunn’s posthoc. See Supplemental Table 1 for group sizes per gene targets. *p < 0.05 for Thrombospondin. Discussion Our results demonstrate that electrospun, supramolecular, biodegradable polycarbonate-bisurea (PC-BU) vascular grafts remained patent for up to two weeks in both sham and CKD rats. During this period, PC-BU grafts underwent rapid degradation accompanied by swift neo-tissue deposition. At two-weeks, neither the presence of CKD nor SDF-1α functionalization affected mechanical characteristics (graft degradation, elastic modulus) or tissue (inflammatory, endothelial, or extracellular matrix (ECM)) markers. After three months, explants displayed extensive graft degradation, neo-vascular tissue formation, and a reduction in inflammatory markers as compared to two-week explants. However, these three-month explants were also characterized by lumen dilations and signs of calcification. Notably, from three weeks onward, scaffold failure with associated mortality was observed, coinciding with progressive scaffold dilatation. The success of in situ tissue engineering relies on an intricate balance between graft degradation and neo-tissue deposition1. Mechanical properties of the graft play a large role in compliance and patency early post-implantation. Upon graft degradation, these dynamics shift with the neo-tissue gradually taking over the mechanical behavior of the graft32,33. Simultaneously, this shift stimulates ECM deposition, thereby strengthening the TEBV load-bearing capacity and contributing to neo-tissue maturation. We previously reported high patency and mechanical stability of PC-UPy TEBVs in rats with and without CKD. However, slowly degrading, retentive materials like PC-UPy have been suggested to favor a prolonged proinflammatory responses 6 and may lead to higher risk of calcification13. We proposed that PC-BU, which has shown favorable degradation kinetics and tissue-performance outcomes in vitro and in vivo19,20,34, would accelerate neo-tissue formation and maturation, thus limiting the risk of adverse effects. Indeed, our data show that the implantation of a PC-BU TEBV led to rapid neo-tissue formation in our animal model. As early as two weeks post-implantation, we found the presence of a (RECA-positive) endothelial cell lining and contractile markers indicating SMCs presence (early marker αSMA and mature SMCs marker Calponin). Previous studies using more retentive materials13,33,35,36 reported substantially less neo-tissue formation in the first weeks, with an endothelial lining appearing only from eight weeks post-implantation. This contrast suggests a close relationship between the dynamics of graft degradation rate versus the timing of neo-tissue formation and maturation. In a subgroup of the animals, we observed that rapid neo-tissue formation at two weeks was followed by maturation and remodeling of the TEBVs, with vascular neo-tissue observed in the explants at three months post-implantation. These explants appeared to demonstrate increased alignment of smooth muscle cell markers, reduced inflammation, and presence of elastin as compared to two weeks explants. However, for three-month PC-BU pristine explants, we were unable to visualize RECA-positive endothelium. Moreover, all three-month explants also showed major vascular dilatations and from three weeks post-implantation onwards, cases of sudden vascular rupture and animal death were observed. SEM analysis revealed local graft erosion and fiber breakage, indicating mechanical weakening that led to rupture. Intact explants consistently displayed preferential aneurysm formation near the aortic bifurcation, eg. the femoral side, a location where aneurysms also commonly occur in the human aorta, likely due to lower shear stress and disturbed flow37. This hemodynamic environment, combined with reduced scaffold integrity, may have contributed to dilatation. Gene expression patterns of TSP-1 appear to confirm this finding. Mainly expressed in endothelial cells and SMCs, TSP-1 is a well-known mechanosensor and upregulation of TSP-1 has been associated with the development of aortic aneurysms38,39. Indeed, TSP-1 expression was primarily upregulated in three-month explants where dilatation occurred. Local scaffold reinforcement to prevent dilation could therefore help maintain the balance between degradation and tissue replacement. Supporting this, PC-BU grafts previously applied as AV-fistulas in our goat model did not exhibit adverse graft remodeling. Although graft degradation proceeded at a comparable rate, dilatation was potentially prevented by the reinforcing anti-kinking coil, which provided additional mechanical strength and stability40. Beyond biomechanical cues, TEBV growth and remodeling heavily rely on inflammation-driven regeneration32. We therefore investigated whether graft biofunctionalization with SDF-1α could positively influence the balance between neo-tissue formation and graft degradation balance in rapidly degrading TEBVs. SDF-1α is a major player in in natural tissue repair and its increased expression is associated with mobilizing and homing of endothelial progenitor cells and anti-inflammatory polarization of monocytes and lymphocytes41. While we previously demonstrated that SDF-1α presence enhances cell recruitment into the TEBV14, in the current study it did not alter inflammatory dynamics nor neo-tissue development. This lack of effect may reflect the rapid degradation of the PB-BU graft leading to an early loss of the bound SDF-1α peptide, diminishing its local activity. Alternatively, the presence of mechanical stimuli, rapid tissue formation, and local ECM production could have outweighed any additional contribution of SDF-1α. As CKD is associated with a chronic inflammatory state1,42, endothelial dysfunction9,11,43, and reduced regenerative capacity, our primary aim focused on the influence of CKD on the balance between graft degradation versus neo-tissue deposition in the context rapidly-degrading vascular PC-BU grafts. Previous studies have suggested that disease, by impairing several key inflammatory and regenerative processes, can influence TEBV outcomes. For example, depleting circulating monocytes44, or blocking angiotensin II type 1 receptor blockade45, processes associated with immune dysfunction and hypertension in CKD, prevented stenosis in healthy animal models. However, in the current study, CKD did not affect TEBV formation after two weeks. This aligns with our previous work using more retentive materials, which also described a limited effect of CKD on neo-tissue formation13. Taken together, these findings indicate that the systemic CKD-associated changes have a minimal impact on early TEBV development. However, other key drivers of neo-tissue formation and development, such as mechanical cues, warrant further investigation. Our study has several limitations. First, due to the progressive nature of CKD, we were unable to evaluate explant TEBVs in CKD animals at three months post-implantation. Future studies investigating the role of CKD on TEBV patency and neo-tissue formation may mitigate this problem by choosing alternative models that preserve the hallmarks of CKD, including proteinuria, hypertension and a pro-inflammatory environment9, while allowing a slower decline of kidney function over time. In rats, uninephrectomy in 10-week-old male and female rats followed by a three-week treatment of deoxycorticosterone acetate (DOCA) through a slow-release pellet (200 mg) plus saline (0.9%,) led to hypertension, mild renal injury and systemic inflammation46. Alternatively, male and female Dahl salt-sensitive rats on a three-week high-salt (4%) diet developed hypertension, proteinuria and renal injury47. In both models, hypertensive and inflammatory responses were however significantly higher in males than in females, emphasizing the importance of also considering sex. Moreover, the results from the uniaxial testing may have overestimated remaining mechanical strength as it was only possible to perform mechanical testing on those parts of the explants that had not been resorbed20,42. Future studies could instead assess total polymer mass or non-invasive in vivo tracking to monitor of graft breakdown over time48. In conclusion, implantation of rapidly-degrading PC-BU TEBVs led to rapid graft degradation accompanied by neo-tissue formation, including an endothelialization, SMC ingrowth, and mechanical stability, at two weeks post-implantation. These outcomes were unaffected by either CKD or SDF-1α functionalization of the graft. At later time points, however, accelerated graft degradation coincided with luminal dilatation and unpredicted graft rupture. While rapidly-degrading TEBVs show the benefit of accelerated neo-tissue formation, care should be taken that mechanical stability is maintained until the neo-tissue has matured sufficiently to bear the physiological hemodynamical load. Supplementary Information Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Supplementary Information 1. Supplementary Information 2. Supplementary Information 3.